Most pigment serums talk as if dark spots are just “too much melanin.” That misses the most important distinction behind CODE3: normal melanin is healthy and protective. The target is abnormal pigment signaling that can push melanocytes toward excess pigment in the wrong places.

That is the insight behind twelve years of formula evolution at Alón Labs. CODE3 is designed to support abnormal-pigment correction while respecting normal pigment, using three upstream pathways rather than a broad “bleaching” frame.

The original CODE3 was formulated by Dr. Daniel Jacobs, a board-certified plastic surgeon, for his wife, who had melasma that did not respond adequately to standard topical treatments. That first version built on proven staples — niacinamide, caffeine, urea, hyaluronic acid, melatonin, and vitamin E — and it worked. But Dr. Jacobs saw a strong foundation and wanted to reach the next level of skin evening and age-defying skincare.

Version two augmented the original base with bakuchiol and quercetin, adding anti-inflammatory and antioxidant coverage that the first formula lacked. The final major advancement came with 10% tranexamic acid, supporting plasmin-mediated pigment signaling upstream of the tyrosine-to-melanin conversion step. CODE3 is one of the few formulas on the market using TXA at this concentration.

Across these three generations of formula development, well over 2,500 customers have used CODE3 across twelve years of direct-to-consumer use. The formula did not replace what worked. It built on it — each generation adding a new mechanism layer while preserving the proven foundation.

Shop CODE3 — $240

Abnormal Pigment vs. Normal Pigment

Melanin is not the enemy. It is part of healthy skin biology and gives skin its natural tone. The problem is not normal pigment; it is abnormal signaling from UV exposure, heat, inflammation, oxidative stress, and plasmin-mediated pathways that can make melanocytes overreact.

That is why CODE3 is not positioned as a broad hydroquinone replacement or a skin-lightening shortcut. The formula story is more precise: TXA, bakuchiol, and quercetin help address upstream signals associated with excess pigment while keeping the goal centered on respecting normal pigment.

The Three Pathways to Pigmentation

To understand why these three ingredients belong together, you need to understand how dark spots form at the cellular level.

Pathway 1: Plasmin-Mediated Pigment Signaling (What TXA Helps Address)

Melanocytes — the cells that produce melanin — are activated by an enzyme cascade. One critical step involves plasmin, a serine protease that promotes melanocyte activity through keratinocyte signaling.

For decades, the standard treatment for this pathway was hydroquinone — effective, but problematic. Hydroquinone carries risks of ochronosis with long-term use and has been banned in the European Union for over-the-counter cosmetic use due to safety concerns. Physicians and consumers have been looking for a replacement that delivers comparable results without the risks.

Tranexamic acid offers a different route. TXA is studied for plasmin-mediated signaling, a pathway that can influence melanocyte activation and downstream pigment production. That makes TXA useful in pigment care without making it a blanket claim that normal pigment is untouched.

The evidence is substantial:

• A 12-week study of topical 3% TXA showed significant MASI (Melasma Area and Severity Index) improvement
• Multiple split-face trials confirm TXA efficacy for melasma and post-inflammatory hyperpigmentation (PIH)
• An expert consensus (PMID: 37264783) established TXA protocols for melasma, with oral administration showing up to 89% reported success rate — supporting the broader evidence for TXA's melanogenesis-inhibiting mechanism

Topical TXA targets the same plasmin-mediated pathway locally, without the systemic considerations of oral administration.

Pathway 2: Inflammation (What Bakuchiol Reduces)

Inflammation drives pigmentation through a separate mechanism. When skin is inflamed — from UV exposure, acne, or irritants — inflammatory cytokines activate melanocytes independently of the plasmin pathway.

This is why post-inflammatory hyperpigmentation (PIH) occurs after acne, aggressive skincare routines, or prolonged sun exposure. The inflammation itself is the trigger.

Bakuchiol provides anti-inflammatory activity through mechanisms that are functionally comparable to retinol:

• A double-blind randomized trial in the British Journal of Dermatology (2019) showed bakuchiol delivered comparable improvements in pigmentation, fine lines, and elasticity versus retinol
• Crucially, bakuchiol users experienced significantly less irritation — meaning the ingredient reduces inflammation without creating new inflammation (unlike retinol, which can paradoxically trigger PIH in sensitive skin)
• Bakuchiol does not cause photosensitivity, so it is safe for AM and PM use year-round

Pathway 3: Oxidative Stress (What Quercetin Scavenges)

UV radiation and environmental pollutants generate reactive oxygen species (ROS) — free radicals that activate melanocytes through yet another pathway independent of plasmin or inflammation.

Emerging evidence supports quercetin's role in this context. A 2024 systematic review and meta-analysis (PMID: 39738831) found that quercetin neutralizes ROS, reduces lipid peroxidation, and upregulates endogenous antioxidant enzymes (SOD, glutathione peroxidase). The same review suggests quercetin may enhance wound healing through fibroblast stimulation and collagen production.

This is the pathway most TXA serums leave entirely unaddressed: oxidative stress continues driving melanocyte activation even when the plasmin and inflammatory pathways are controlled.

How CODE3 Was Developed

CODE3 evolved through three generations. The original formula (niacinamide, caffeine, urea, hyaluronic acid, melatonin, vitamin E) established the foundation. Version two added bakuchiol and quercetin to cover inflammation and oxidative stress. The current formula added 10% TXA — one of the highest concentrations on the market — to directly target melanogenesis. Each generation built on the last rather than discarding it.

How to Use CODE3

• Application: Apply to clean skin AM and PM
• Layer: Under moisturizer and sunscreen (AM) or under moisturizer (PM)
• Pair with: Broad-spectrum mineral SPF 30+ during the day
• Timeline: Most users see visible improvement in pigmentation within 4–8 weeks of consistent use

The Bottom Line

Abnormal pigment is often a multi-signal problem. Tranexamic acid helps address plasmin-mediated pigment signaling. Bakuchiol helps reduce the irritation-inflammation loop. Quercetin helps address oxidative stress. CODE3 combines all three in a patent-pending formula refined over twelve years of direct-to-consumer use.

If you have been using a single-ingredient TXA serum and still seeing uneven pigment return, the answer may not be a harsher routine. It may be broader mechanism coverage that stays focused on abnormal pigment while respecting normal melanin.

Shop CODE3 — $240

---

References:
Oral Tranexamic Acid for Melasma: Evidence and Experience-Based Consensus. PMID: 37264783 (2023)
Bakuchiol vs. retinol: prospective, randomized, double-blind study. British Journal of Dermatology, 2019;180(2):289-296
Quercetin as a therapeutic agent for skin: systematic review and meta-analysis. PMID: 39738831 (2024)
Topical tranexamic acid as a promising treatment for melasma. PMC 4235096

---

Alón Labs makes physician-developed topicals for abnormal pigment care that respects normal pigment. CODE3 is a patent-pending formula developed by Dr. Daniel Jacobs, a board-certified plastic surgeon.